Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1721-1730 Newer>

The Motley Fool January 28, 2005 Stephen D. Simpson	SurModics Stays in the Hot Spot Medical technology coatings specialist occupies the hazy world between biotech and medical devices. Though priced roughly in line with peers like Flamel or Nektar, the stock trades at almost 10 times sales and even the forward P/E is a robust 26.5.
The Motley Fool January 28, 2005 Karl Thiel	Will the FDA Kill Biotech? Proposed legislation could spell changes across the pharmaceutical world. Investors are right to be nervous.
InternetNews January 27, 2005 Roy Mark	Bush Pledges E-Medical Records For Americans President calls for increased spending on IT health initiatives.
The Motley Fool January 27, 2005 Stephen D. Simpson	Generics Bout Gets Bloody Bristol-Myers Squibb struggles to keep growing amid patent expirations.
The Motley Fool January 27, 2005 Stephen D. Simpson	AstraZeneca Shines, for Now The British-Swedish drug company has a great quarter, but the future looks dimmer.
The Motley Fool January 27, 2005 Brian Gorman	Covance's Higher Performance The provider of drug development services' productivity gains and bundled service strategy are driving results.
The Motley Fool January 27, 2005 Wherrett & Yelovich	Billion-Dollar Markets Nanoparticulates offer golden opportunities for investors... if you know where to look.
The Motley Fool January 26, 2005 John Bluis	Genzyme Feels the Heat Drug company faces first true competition to its enzyme replacement therapy for Gaucher disease.
Insurance & Technology January 25, 2005 Jim Hatfield	Click to Pay Improvements in operational efficiency can help healthcare organizations keep themselves off the critical list. With that in mind, in 2000, Harvard Pilgrim Health Care turned to online billing to expedite receivables and boost customer service.
The Motley Fool January 26, 2005 Stephen D. Simpson	Sanofi's Balancing Act A broad portfolio of drugs helps the French pharmaceutical stay ahead of its peers. It's a good option for investors who want a strong growth stock in the pharmaceutical space but don't want to take on the risks of turnarounds or litigation.
<Older 1721-1730 Newer> Return to current articles.